MCID: VRL017
MIFTS: 37

Viral Hemorrhagic Fever

Categories: Rare diseases, Infectious diseases

Aliases & Classifications for Viral Hemorrhagic Fever

Summaries for Viral Hemorrhagic Fever

MalaCards based summary : Viral Hemorrhagic Fever, also known as hemorrhagic fevers, viral, is related to hemorrhagic fever and lassa fever, and has symptoms including gingival bleeding, hearing impairment and epistaxis. An important gene associated with Viral Hemorrhagic Fever is LBR (Lamin B Receptor). The drugs Histamine and Ketotifen have been mentioned in the context of this disorder. Affiliated tissues include testes, endothelial and t cells.

Wikipedia : 72 Viral hemorrhagic fevers (VHFs) are a diverse group of animal and human illnesses in which fever and... more...

Related Diseases for Viral Hemorrhagic Fever

Diseases in the Hemorrhagic Fever family:

Viral Hemorrhagic Fever

Diseases related to Viral Hemorrhagic Fever via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 14)
# Related Disease Score Top Affiliating Genes
1 hemorrhagic fever 11.5
2 lassa fever 11.3
3 dengue disease 11.1
4 marburg hemorrhagic fever 11.0
5 omsk hemorrhagic fever 11.0
6 kyasanur forest disease 11.0
7 ebola hemorrhagic fever 11.0
8 hantavirus pulmonary syndrome 10.0
9 hemorrhagic fever with renal syndrome 9.9
10 rift valley fever 9.9
11 coccidioidomycosis 9.9
12 dengue virus 9.7
13 thrombocytopenia 9.7
14 vascular disease 9.7

Graphical network of the top 20 diseases related to Viral Hemorrhagic Fever:



Diseases related to Viral Hemorrhagic Fever

Symptoms & Phenotypes for Viral Hemorrhagic Fever

Human phenotypes related to Viral Hemorrhagic Fever:

31 (show all 24)
# Description HPO Frequency HPO Source Accession
1 gingival bleeding 31 frequent (33%) HP:0000225
2 hearing impairment 31 occasional (7.5%) HP:0000365
3 epistaxis 31 frequent (33%) HP:0000421
4 skin rash 31 frequent (33%) HP:0000988
5 seizures 31 occasional (7.5%) HP:0001250
6 decreased liver function 31 frequent (33%) HP:0001410
7 thrombocytopenia 31 frequent (33%) HP:0001873
8 leukopenia 31 frequent (33%) HP:0001882
9 subcutaneous hemorrhage 31 frequent (33%) HP:0001933
10 fever 31 hallmark (90%) HP:0001945
11 diarrhea 31 frequent (33%) HP:0002014
12 nausea and vomiting 31 frequent (33%) HP:0002017
13 abdominal pain 31 frequent (33%) HP:0002027
14 migraine 31 frequent (33%) HP:0002076
15 gastrointestinal hemorrhage 31 frequent (33%) HP:0002239
16 encephalitis 31 occasional (7.5%) HP:0002383
17 arthralgia 31 frequent (33%) HP:0002829
18 myalgia 31 frequent (33%) HP:0003326
19 reduced consciousness/confusion 31 occasional (7.5%) HP:0004372
20 spontaneous abortion 31 frequent (33%) HP:0005268
21 fatigue 31 hallmark (90%) HP:0012378
22 recurrent bronchiolitis 31 occasional (7.5%) HP:0100501
23 retrobulbar optic neuritis 31 occasional (7.5%) HP:0100654
24 chest pain 31 frequent (33%) HP:0100749

UMLS symptoms related to Viral Hemorrhagic Fever:


pruritus, fever

Drugs & Therapeutics for Viral Hemorrhagic Fever

Drugs for Viral Hemorrhagic Fever (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 119)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Histamine Approved, Investigational Phase 4 51-45-6, 75614-87-8 774
2
Ketotifen Approved Phase 4 34580-13-7, 34580-14-8 3827
3
Benzocaine Approved, Investigational Phase 4,Phase 1,Phase 2 1994-09-7, 94-09-7 2337
4
Menthol Approved Phase 4 2216-51-5 16666
5 tannic acid Approved, Nutraceutical Phase 4,Phase 1,Phase 2
6
Histamine Phosphate Phase 4 51-74-1 65513
7 Neurotransmitter Agents Phase 4
8 Vaccines Phase 4,Phase 3,Phase 2,Phase 1
9 Histamine Antagonists Phase 4
10 Histamine H1 Antagonists Phase 4
11 Dermatologic Agents Phase 4,Phase 1,Phase 2
12 Anti-Allergic Agents Phase 4
13 Antipruritics Phase 4
14 Vasoconstrictor Agents Phase 4
15
Ivermectin Approved, Investigational, Vet_approved Phase 2, Phase 3 70288-86-7 46936176 6474909
16
Loperamide Approved Phase 2, Phase 3 53179-11-6 3955
17
Vitamin A Approved, Nutraceutical, Vet_approved Phase 3 68-26-8, 11103-57-4 445354
18
Lactitol Investigational Phase 3 585-86-4 3871
19 DEET Phase 3
20 Pharmaceutical Solutions Phase 3,Phase 2,Phase 1
21 Anti-Infective Agents Phase 2, Phase 3, Phase 1
22 Immunoglobulins Phase 3,Phase 1,Phase 2
23 Insect Repellents Phase 3
24 Protective Agents Phase 3,Phase 1
25 Antibodies Phase 3,Phase 1,Phase 2
26 Antiparasitic Agents Phase 2, Phase 3,Phase 1
27 Heptavalent Pneumococcal Conjugate Vaccine Phase 3,Phase 2
28 Vitamins Phase 3,Phase 2
29 Antibodies, Blocking Phase 3
30 Anti-Bacterial Agents Phase 2, Phase 3,Phase 1
31 Krestin Phase 3,Phase 2,Phase 1
32 Iron-Dextran Complex Phase 3
33 Retinol palmitate Phase 3
34 Micronutrients Phase 3
35 Trace Elements Phase 3
36 Antioxidants Phase 3
37 retinol Nutraceutical Phase 3
38
chloroquine Approved, Investigational, Vet_approved Phase 1, Phase 2 54-05-7 2719
39
Irbesartan Approved, Investigational Phase 1, Phase 2 138402-11-6 3749
40
Ribavirin Approved Phase 2 36791-04-5 37542
41
Hydrocortisone Approved, Vet_approved Phase 2 50-23-7 657311 5754
42
Angiotensin II Approved, Investigational Phase 1, Phase 2 68521-88-0, 4474-91-3, 11128-99-7 172198 65143
43
Azithromycin Approved Phase 1, Phase 2 83905-01-5 53477736 447043 55185
44
Sunitinib Approved, Investigational Phase 1, Phase 2 341031-54-7, 557795-19-4 5329102
45
Coal tar Approved Phase 1, Phase 2 8007-45-2
46
Epinephrine Approved, Vet_approved Phase 2,Phase 1 51-43-4 5816
47
Neomycin Approved, Vet_approved Phase 1, Phase 2 1404-04-2 8378
48
Artemether Approved Phase 2 71963-77-4 68911 119380
49
Lumefantrine Approved Phase 2 82186-77-4 6437380
50 Racepinephrine Approved Phase 2,Phase 1 329-65-7

Interventional clinical trials:

(show top 50) (show all 247)

# Name Status NCT ID Phase Drugs
1 Ketotifen as a Treatment for Vascular Leakage During Dengue Fever Unknown status NCT02673840 Phase 4 Ketotifen;Placebo
2 High Frequency Ventilation During Off Pump Coronary Artery Bypass Graft (CABG) Completed NCT00863044 Phase 4
3 International Multicenter Study of the Immunogenicity of Medicinal Product GamEvac-Combi Recruiting NCT03072030 Phase 4
4 Immunogenicity of Co-administered Yellow Fever and Measles, Mumps, and Rubella (MMR) Vaccines Recruiting NCT03368495 Phase 4
5 Immunogenicity and Safety of the Yellow Fever Vaccine in HIV Infected Individuals Recruiting NCT03132311 Phase 4
6 Immunity Period After One Dose of Yellow Fever Vaccine in Adults and Children (Paraiba Study) Recruiting NCT02555072 Phase 4
7 Immunogenicity and Safety of Fractional Doses of Yellow Fever Vaccines (YEFE) Active, not recruiting NCT02991495 Phase 4
8 Study of a Novel Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 14 Years in Asia Unknown status NCT01373281 Phase 3
9 Effect of Hypertonic Sodium Lactate on sVCAM-1 Level as Surrogate Marker of Endothelial Capillary Leakage in Pediatric Dengue Shock Syndrome Patients (DSS) Unknown status NCT00966628 Phase 3 Hypertonic sodium lactate;Ringer's lactate
10 Efficacy and Safety of Ivermectin Against Dengue Infection Unknown status NCT02045069 Phase 2, Phase 3 2 days Ivermectin;3 days Ivermectin;Placebo
11 Clinical Evaluation of Insect Repellent and Insecticide Treated Nets in Lao PDR Unknown status NCT00938379 Phase 3 20% deet insect repellent;placebo control
12 STRIVE (Sierra Leone Trial to Introduce a Vaccine Against Ebola) Completed NCT02378753 Phase 2, Phase 3
13 Study of a Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 11 Years in Malaysia Completed NCT01254422 Phase 3
14 Study to Evalutate Long-term Immunity of Hantavax in High Risk Population of HFRS Completed NCT02360514 Phase 3 Hantavax injection
15 Study of a Booster Injection of Pentaxim™ Vaccine Administered With Dengue Vaccine in Healthy Toddlers Completed NCT01411241 Phase 3
16 Emergency Evaluation of Convalescent Plasma for Ebola Viral Disease (EVD) in Guinea Completed NCT02342171 Phase 2, Phase 3
17 Study of a Tetravalent Dengue Vaccine in Healthy Adults in Australia Completed NCT01134263 Phase 3
18 Study of Yellow Fever Vaccine Administered With Tetravalent Dengue Vaccine in Healthy Toddlers Completed NCT01436396 Phase 3
19 Evaluation of the Safety and Immunogenicity of Three Consistency Lots and a High-Dose Lot of rVSV-ZEBOV-GP (V920 Ebola Vaccine) in Healthy Adults (V920-012) Completed NCT02503202 Phase 3
20 A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of Select Travel Vaccines When Administered Concomitantly With MenACWY in Adults Completed NCT01466387 Phase 3
21 Long-term Safety Follow-up of Participants Exposed to the Candidate Ebola Vaccines Ad26.ZEBOV and/or MVA-BN-Filo Recruiting NCT02661464 Phase 3
22 Staged Phase 3 Study to Assess the Safety and Immunogenicity of Ebola Candidate Vaccines Ad26.ZEBOV and MVA-BN-Filo During Implementation of Stages 1 and 2 Recruiting NCT02509494 Phase 3
23 Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) in Adolescents in Non-Endemic Area(s) Recruiting NCT03341637 Phase 3
24 Phase III Trial to Evaluate Efficacy and Safety of a Tetravalent Dengue Vaccine Recruiting NCT02406729 Phase 3
25 Study of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Adacel® in Healthy Subjects Active, not recruiting NCT02992418 Phase 3
26 Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Gardasil® Active, not recruiting NCT02993757 Phase 3
27 Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Cervarix® Active, not recruiting NCT02979535 Phase 3
28 Study of a Novel Tetravalent Dengue Vaccine in Healthy Children and Adolescents Aged 9 to 16 Years in Latin America Active, not recruiting NCT01374516 Phase 3
29 Immunogenicity and Safety Study of GSK Biologicals' Candidate Malaria Vaccine Given at 6, 7.5 and 9 Months of Age in Co-administration With Measles, Rubella and Yellow Fever (YF) Vaccines Followed by a Booster of the Malaria Vaccine. Active, not recruiting NCT02699099 Phase 3
30 The Yellow Fever Vaccine Immunity in HIV Infected Patients : Development of New Assays for Virological and Immunological Monitoring in HIV Infected Patient. Active, not recruiting NCT01426243 Phase 3
31 Lot-to-lot Consistency of 3 Lots of Tetravalent Dengue Vaccine (TDV) in Non-endemic Country(Ies) for Dengue Not yet recruiting NCT03423173 Phase 3
32 Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) Administered With a Yellow Fever Vaccine in Adults Not yet recruiting NCT03342898 Phase 3
33 Providing Additional Information on the Safety and Effectiveness of an Ebola Vaccine Suspended NCT03161366 Phase 3
34 Clinical Study to Assess Efficacy and Safety of Amiodarone in Treating Patients With Ebola. Virus Disease (EVD) in Sierra Leone. EASE (EMERGENCY Amiodarone Study Against Ebola) Withdrawn NCT02307591 Phase 2, Phase 3 Best Supportive Care;Best Supportive Care + Amiodarone
35 Chinese and Western Medicine Treatment of Fever Associated With Bleeding Symptoms Unknown status NCT01973855 Phase 2 Western Medicine;TCM and Western Medicine
36 Treatment of Japanese Encephalitis Unknown status NCT00216268 Phase 2 Ribavirin
37 Multiple Treatments for Ebola Virus Disease (EVD) Unknown status NCT02380625 Phase 1, Phase 2 Azithromycin;Sunitinib and Erlotinib;Atorvastatin and Irbesartan
38 The Effect of Chloroquine in the Treatment of Patients With Dengue Unknown status NCT00849602 Phase 1, Phase 2 Placebo;Chloroquine
39 Activated Recombinant Human Factor VII in Patients With Dengue Haemorrhagic Fever Completed NCT01601613 Phase 2 activated recombinant human factor VII;placebo
40 Study of CYD Dengue Vaccine in Healthy Children and Adolescents in South America Completed NCT01187433 Phase 2
41 A Study of Dengue Vaccine in Healthy Toddlers Aged 12 to 15 Months in the Philippines Completed NCT01064141 Phase 2
42 Immunogenicity and Safety of Three Formulations of Dengue Vaccines in Healthy Adults Aged 18 to 45 Years in the US Completed NCT00617344 Phase 2
43 Study of a Tetravalent Dengue Vaccine in Healthy Adult Subjects Aged 18 to 45 Years in India Completed NCT01550289 Phase 2
44 Safety and Immunogenicity of Formulations of Dengue Vaccines in Healthy Flavivirus-Naïve Adults Completed NCT00740155 Phase 2
45 Study of ChimeriVax™ Dengue Tetravalent Vaccine in Adult Subjects Completed NCT00730288 Phase 2
46 Immunogenicity and Safety of Sanofi Pasteur's CYD Dengue Vaccine in Healthy Children and Adolescents in Latin America Completed NCT00993447 Phase 2
47 Study of Sanofi Pasteur's CYD Dengue Vaccine in Healthy Subjects in Singapore Completed NCT00880893 Phase 2
48 Study of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Subjects Completed NCT00875524 Phase 2
49 Efficacy and Safety of Dengue Vaccine in Healthy Children Completed NCT00842530 Phase 2
50 Study of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Peruvian Children Aged 2 to 11 Years Completed NCT00788151 Phase 2

Search NIH Clinical Center for Viral Hemorrhagic Fever

Genetic Tests for Viral Hemorrhagic Fever

Anatomical Context for Viral Hemorrhagic Fever

MalaCards organs/tissues related to Viral Hemorrhagic Fever:

38
Testes, Endothelial, T Cells, Liver, Skin, Kidney

Publications for Viral Hemorrhagic Fever

Articles related to Viral Hemorrhagic Fever:

(show top 50) (show all 66)
# Title Authors Year
1
Murine Models for Viral Hemorrhagic Fever. ( 28986841 )
2018
2
A Primate Model for Viral Hemorrhagic Fever. ( 28986843 )
2018
3
Disposable cartridge platform for rapid detection of viral hemorrhagic fever viruses. ( 28194457 )
2017
4
Exploring the Immunopathogenesis of Viral Hemorrhagic Fever in Mice with a Humanized Immune System. ( 29018450 )
2017
5
Viral hemorrhagic fever in the tropics: Report from the task force on tropical diseases by the World Federation of Societies of Intensive and Critical Care Medicine. ( 29128377 )
2017
6
Development and preliminary evaluation of a multiplexed amplification and next generation sequencing method for viral hemorrhagic fever diagnostics. ( 29155823 )
2017
7
Molecular pathogenesis of viral hemorrhagic fever. ( 28555386 )
2017
8
The Epi Info Viral Hemorrhagic Fever (VHF) Application: A Resource for Outbreak Data Management and Contact Tracing in the 2014-2016 West Africa Ebola Epidemic. ( 27587635 )
2016
9
Hospital Preparations for Viral Hemorrhagic Fever Patients and Experience Gained from Admission of an Ebola Patient. ( 26812146 )
2016
10
HMGB1 Is a Potential Biomarker for Severe Viral Hemorrhagic Fevers. ( 27348219 )
2016
11
Lujo viral hemorrhagic fever: considering diagnostic capacity and preparedness in the wake of recent Ebola and Zika virus outbreaks. ( 27593704 )
2016
12
Systems Pharmacology Uncovers the Multiple Mechanisms of Xijiao Dihuang Decoction for the Treatment of Viral Hemorrhagic Fever. ( 27239215 )
2016
13
Animal models for some important RNA viruses of public health concern in SEARO countries: Viral hemorrhagic fever. ( 25815861 )
2015
14
A Multiplex PCR/LDR Assay for the Simultaneous Identification of Category A Infectious Pathogens: Agents of Viral Hemorrhagic Fever and Variola Virus. ( 26381398 )
2015
15
Does Viral Hemorrhagic Fever Represent Reactive Hemophagocytic Syndrome? ( 26136549 )
2015
16
Alterations in favipiravir (T-705) pharmacokinetics and biodistribution in a hamster model of viral hemorrhagic fever. ( 26186980 )
2015
17
Addressing the Complications of Ebola and Other Viral Hemorrhagic Fever Infections: Using Insights from Bacterial and Fungal Sepsis. ( 26425845 )
2015
18
Viral Hemorrhagic Fever Diagnostics. ( 26354968 )
2015
19
Animal Models for Viral Hemorrhagic Fever. ( 24690109 )
2014
20
Viral hemorrhagic fever cases in the country of Georgia: Acute Febrile Illness Surveillance Study results. ( 24891463 )
2014
21
Development and validation of serological assays for viral hemorrhagic fevers and determination of the prevalence of Rift Valley fever in Borno State, Nigeria. ( 25344695 )
2014
22
Animal models of viral hemorrhagic fever. ( 25448088 )
2014
23
Simultaneous detection of IgG antibodies associated with viral hemorrhagic fever by a multiplexed Luminex-based immunoassay. ( 24631566 )
2014
24
Diagnostic schemes for reducing epidemic size of African viral hemorrhagic fever outbreaks. ( 25212079 )
2014
25
The pathogenesis of severe Fever with thrombocytopenia syndrome virus infection in alpha/beta interferon knockout mice: insights into the pathologic mechanisms of a new viral hemorrhagic Fever. ( 24257618 )
2014
26
Genomic analysis of filoviruses associated with four viral hemorrhagic fever outbreaks in Uganda and the Democratic Republic of the Congo in 2012. ( 23711383 )
2013
27
Outbreak of viral hemorrhagic fever caused by dengue virus type 3 in Al-Mukalla, Yemen. ( 23497142 )
2013
28
Viral hemorrhagic fever viruses. ( 24314803 )
2013
29
Alkhurma viral hemorrhagic fever virus: proposed guidelines for detection, prevention, and control in Saudi Arabia. ( 22860139 )
2012
30
Simian hemorrhagic fever virus infection of rhesus macaques as a model of viral hemorrhagic fever: clinical characterization and risk factors for severe disease. ( 22014505 )
2011
31
Aerosol exposure to the angola strain of marburg virus causes lethal viral hemorrhagic Fever in cynomolgus macaques. ( 20807825 )
2010
32
Reappearance of viral hemorrhagic fever with renal syndrome in northwestern Greece. ( 19926507 )
2010
33
Lessons learned during active epidemiological surveillance of Ebola and Marburg viral hemorrhagic fever epidemics in Africa. ( 21413569 )
2010
34
Assessing changes in vascular permeability in a hamster model of viral hemorrhagic fever. ( 20846417 )
2010
35
Gene expression in primate liver during viral hemorrhagic fever. ( 19216742 )
2009
36
Viral hemorrhagic fever-induced acute kidney injury. ( 18620963 )
2008
37
Immunopathogenesis of hantavirus pulmonary syndrome and hemorrhagic fever with renal syndrome: Do CD8+ T cells trigger capillary leakage in viral hemorrhagic fevers? ( 17897725 )
2007
38
MassTag polymerase chain reaction for differential diagnosis of viral hemorrhagic fever. ( 16704825 )
2006
39
Viral hemorrhagic fever - an ICU perspective. ( 16827967 )
2006
40
Pathogenesis of viral hemorrhagic fever. ( 15955687 )
2005
41
Alkhumra virus infection, a new viral hemorrhagic fever in Saudi Arabia. ( 16038757 )
2005
42
Correction: Stampidine prevents mortality in an experimental mouse model of viral hemorrhagic fever caused by lassa virus. ( 15171793 )
2004
43
Emerging roles of tissue factor in viral hemorrhagic fever. ( 15324737 )
2004
44
Role of specific CD8+ T cells in the severity of a fulminant zoonotic viral hemorrhagic fever, hantavirus pulmonary syndrome. ( 14978138 )
2004
45
Treating viral hemorrhagic fever. ( 14600838 )
2003
46
Viral hemorrhagic fever--a vascular disease? ( 12783108 )
2003
47
Implementation of the Canadian contingency plan for a case of suspected viral hemorrhagic fever. ( 12725358 )
2003
48
Viral hemorrhagic fevers including hantavirus pulmonary syndrome in the Americas. ( 12489291 )
2002
49
Mitogen therapy for biological warfare/terrorist attacks and viral hemorrhagic fever control. ( 11915170 )
2002
50
Viral hemorrhagic fever in Pakistan: awareness among health care personnel. ( 12174494 )
2002

Variations for Viral Hemorrhagic Fever

Expression for Viral Hemorrhagic Fever

Search GEO for disease gene expression data for Viral Hemorrhagic Fever.

Pathways for Viral Hemorrhagic Fever

GO Terms for Viral Hemorrhagic Fever

Sources for Viral Hemorrhagic Fever

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....